Biosimilars Access and Affordability Act

The Congressional Research Service hasn't published a summary of this bill yet. They usually follow within weeks of introduction.

Our plain-language breakdown, with what it means for you and the case for and against, is written once a bill starts to move.

1. 2026-09-28Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.House floor actions
2. 2026-09-28Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.House floor actions
3. 2026-09-28Introduced in HouseLibrary of Congress
4. 2026-09-28Introduced in HouseLibrary of Congress

Show key steps only

Cosponsors

• Rep. Jake Auchincloss D-MA-4
• Rep. Donald G. Davis D-NC-1
• Rep. John Joyce R-PA-13
• Rep. Nathaniel Moran R-TX-1
• Rep. Kevin Mullin D-CA-15
• Rep. Jimmy Panetta D-CA-20
• Rep. Scott H. Peters D-CA-50
• Rep. Linda T. Sánchez D-CA-38
• Rep. Rudy Yakym R-IN-2